Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
Last trade$2.02
Day change-$0.19 (-8.60%)
Day range$1.99 – $2.40
Volume155,700
Market cap$68M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for CNXU.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for CNXU.
Recent news
Company coverage with links to the original publishers.
Analyst Chris Graebe highlights four private companies that delivered substantial returns to early investors before going public: Starfighters Space (FJET) with a 7x return, BeatBox Beverages with a 5-6x return via acquisition, Eagle Nuclear Energy Corp. (NUCL) with a 4x peak return, and Conexeu Sciences Inc. (CNXU) with an 8x return. The article emphasizes that the biggest IPO gains typically accrue to early private investors, not those entering at public listing, and discusses the JOBS Act's Regulation A offerings as a pathway for retail investors to access pre-IPO opportunities.
Conexeu Sciences Inc. (CNXU) commenced trading on Nasdaq on May 21, 2026, as a regenerative tissue platform company. The company's proprietary CXU™ extracellular matrix platform is designed to scale across multiple markets including wound care, breast reconstruction, and aesthetic medicine without reformulation. The company targets a 510(k) submission in early 2027 and holds issued patents across major markets with no royalty obligations.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.